Literature DB >> 4217466

Tobramycin treatment of pseudomonas aeruginosa infections in cystic fibrosis.

G E Hoff, P O Schiotz, J Paulsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4217466     DOI： 10.3109/inf.1974.6.issue-4.07

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN： 0036-5548


× No keyword cloud information.
  8 in total

1.  Tobramycin dosage recommendation in patients with cystic fibrosis.

Authors:  R L Davis; P Mendelman; B Ramsey; A L Smith
Journal:  Infection       Date:  1989 Jan-Feb       Impact factor: 3.553

2.  Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.

Authors:  S S Pedersen; T Jensen; D Osterhammel; P Osterhammel
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

3.  Tobramycin nephrotoxicity. A prospective clinical study.

Authors:  A Coca; J Blade; A Martinez; F Segura; E Soriano; M Ribas-Mundo
Journal:  Postgrad Med J       Date:  1979-11       Impact factor: 2.401

4.  Therapeutic evaluation of immunomodulators in reducing surgical wound infection.

Authors:  Foyez Mahmud; Ruchi Roy; Mohamed F Mohamed; Anahita Aboonabi; Mario Moric; Kamran Ghoreishi; Mohammad Bayat; Timothy M Kuzel; Jochen Reiser; Sasha H Shafikhani
Journal:  FASEB J       Date:  2022-01       Impact factor: 5.834

Review 5.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

6.  Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis.

Authors:  A J Martin; C A Smalley; R H George; D E Healing; C M Anderson
Journal:  Arch Dis Child       Date:  1980-08       Impact factor: 3.791

7.  Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.

Authors:  U Paporisz; H G Posselt; R Wönne; W Ristow; D Röser; H Knothe; S W Bender
Journal:  Eur J Pediatr       Date:  1979-04-03       Impact factor: 3.183

8.  A Genetic Screen Reveals Novel Targets to Render Pseudomonas aeruginosa Sensitive to Lysozyme and Cell Wall-Targeting Antibiotics.

Authors:  Kang-Mu Lee; Keehoon Lee; Junhyeok Go; In Ho Park; Jeon-Soo Shin; Jae Young Choi; Hyun Jik Kim; Sang Sun Yoon
Journal:  Front Cell Infect Microbiol       Date:  2017-03-01       Impact factor: 5.293
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.